Liquidity and Capital Resources (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
Estimated projected expenditure [Line Items]
Cash and cash equivalents	$ 6,036,220	$ 14,344,088	$ 12,453,637	$ 17,988,590
Short-term investments	17,000,000	24,000,000
Net proceeds from underwritten public offering	24,100,000
Currently projected expenditures for clinical programs	28,200,000
Aldoxorubicin [Member]
Estimated projected expenditure [Line Items]
Currently projected expenditures for clinical programs	16,200,000
Other Programs [Member]
Estimated projected expenditure [Line Items]
Currently projected expenditures for clinical programs	300,000
General Operation [Member]
Estimated projected expenditure [Line Items]
Currently projected expenditures for clinical programs	4,800,000
Other General and Administrative Expenses [Member]
Estimated projected expenditure [Line Items]
Currently projected expenditures for clinical programs	$ 6,900,000